戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 specific suppression of ongoing experimental allergic encephalomyelitis.
2 and its principal animal model, experimental allergic encephalomyelitis.
3 that confers resistance against experimental allergic encephalomyelitis.
4 o appropriately resolve induced experimental allergic encephalomyelitis.
5 autoimmune encephalomyelitis or experimental allergic encephalomyelitis.
6  protection of the mice against experimental allergic encephalomyelitis.
7 immunity and protection against experimental allergic encephalomyelitis.
8 nesis of multiple sclerosis and experimental allergic encephalomyelitis.
9 immune-mediated illness such as experimental allergic encephalomyelitis.
10 ible to the active induction of experimental allergic encephalomyelitis.
11 , and amyloidosis and mice with experimental allergic encephalomyelitis.
12  model of MS, chronic relapsing experimental allergic encephalomyelitis.
13 chanism for the pathogenesis of experimental allergic encephalomyelitis.
14 multiple sclerosis and the marmoset model of allergic encephalomyelitis.
15 uestion the Th1-Th2 paradigm in experimental allergic encephalomyelitis.
16 n-reactive T cells and modulate experimental allergic encephalomyelitis.
17 ted autoimmune diseases such as experimental allergic encephalomyelitis.
18 r cells capable of transferring experimental allergic encephalomyelitis.
19 ein (MOG)(35\x{2013}55)-induced experimental allergic encephalomyelitis.
20 e animals were able to overcome experimental allergic encephalomyelitis.
21 lly interconvert respond during experimental allergic encephalomyelitis.
22 evere disease manifestations in experimental allergic encephalomyelitis.
23 ediated protection of Tregs and experimental allergic encephalomyelitis.
24 that confers resistance against experimental allergic encephalomyelitis.
25 ing a model autoimmune disease, experimental allergic encephalomyelitis.
26 IMP1 promotes neuropathology in experimental allergic encephalomyelitis.
27 h less severe acute early-phase experimental allergic encephalomyelitis.
28 vo effects of tyrphostin B42 in experimental allergic encephalomyelitis, a Th1 cell-mediated autoimmu
29 n their Point of View entitled "Experimental Allergic Encephalomyelitis: A Misleading Model of Multip
30 specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the
31 meliorated adoptive transfer of experimental allergic encephalomyelitis, an animal model of MS, via T
32 eat chronic relapsing-remitting experimental allergic encephalomyelitis, an animal model of multiple
33  were effective in treatment of experimental allergic encephalomyelitis, an animal model of multiple
34 es Tregs and protects mice from experimental allergic encephalomyelitis, an animal model of multiple
35 e for oligodendrocytes (OLG) in experimental allergic encephalomyelitis, an animal model of multiple
36 al and pathological features of experimental allergic encephalomyelitis, an animal model of multiple
37                                 Experimental allergic encephalomyelitis, an autoimmune disorder media
38 ation of Th1 and Th2 subsets in experimental allergic encephalomyelitis, an autoimmune disorder.
39 meliorated clinical severity of experimental allergic encephalomyelitis, an effect that partially inv
40 red autoimmune disease locus in experimental allergic encephalomyelitis and experimental allergic orc
41 ector memory T (T(EM)) cells in experimental allergic encephalomyelitis and in myelin-specific T cell
42 ffective both in suppression of experimental allergic encephalomyelitis and in the treatment of relap
43 ffective both in suppression of experimental allergic encephalomyelitis and in the treatment of relap
44      We report that MOBP causes experimental allergic encephalomyelitis and is associated with multip
45 enic mice displayed more severe experimental allergic encephalomyelitis and lupus.
46 in autoimmune processes such as experimental allergic encephalomyelitis and lupus.
47 ggest that its effectiveness in experimental allergic encephalomyelitis and multiple sclerosis may be
48 imilar results correlating with experimental allergic encephalomyelitis and orchitis susceptibility w
49 a concomitant susceptibility to experimental allergic encephalomyelitis and significant protection ag
50     This is based on studies in experimental allergic encephalomyelitis and the demonstration that PB
51 mental models of demyelination, experimental allergic encephalomyelitis and Theiler's murine encephal
52 ls are generated in vivo during experimental allergic encephalomyelitis, and adoptively transferred T
53 ies such as multiple sclerosis, experimental allergic encephalomyelitis, and Alzheimer's disease, sug
54 inally, in the in vivo model of experimental allergic encephalomyelitis, anti-B7.2 mAb treatment abro
55 n a conventional mouse model of experimental allergic encephalomyelitis are dependent upon the produc
56 TMEV)-induced demyelination and experimental allergic encephalomyelitis are the principal immunologic
57  tolerance and developed severe experimental allergic encephalomyelitis as well as spontaneous autoim
58 st disappointing aspect of EAE [experimental allergic encephalomyelitis] as a potential model for MS
59 nical and pathological signs of experimental allergic encephalomyelitis by causing the deletion of en
60 cities in the marmoset model of experimental allergic encephalomyelitis, by means of a combinatorial
61 ity in animal models, including experimental allergic encephalomyelitis, collagen and adjuvant-induce
62 es in autoimmune destruction in experimental allergic encephalomyelitis, collagen-induced arthritis a
63               Chronic relapsing experimental allergic encephalomyelitis (CREAE) is an autoimmune mode
64 utoreactive T cell response and experimental allergic encephalomyelitis development in an IL-10-depen
65 in vivo of CD4+ T-cell-mediated experimental allergic encephalomyelitis disease in the SJL mouse mode
66 hat animals with ongoing active experimental allergic encephalomyelitis dramatically reduce the sever
67 adult male SJL are resistant to experimental allergic encephalomyelitis due to an APC-dependent induc
68 ceptibility to actively induced experimental allergic encephalomyelitis (EAE) and experimental allerg
69 l models of autoimmune disease, experimental allergic encephalomyelitis (EAE) and experimental myocar
70                                 Experimental allergic encephalomyelitis (EAE) and its human disease c
71                                 Experimental allergic encephalomyelitis (EAE) and multiple sclerosis
72                                 Experimental allergic encephalomyelitis (EAE) and Theiler's murine en
73  two autoimmune disease models, experimental allergic encephalomyelitis (EAE) and type 1 diabetes (T1
74 igen-specific effector cells in experimental allergic encephalomyelitis (EAE) are a continuing challe
75 ment of neurological disease in experimental allergic encephalomyelitis (EAE) but not during clearanc
76 )) develop less severe clinical experimental allergic encephalomyelitis (EAE) compared to either Esr1
77 fied CTL ameliorated or blocked experimental allergic encephalomyelitis (EAE) disease mediated by MBP
78  protein (CRP) protects against experimental allergic encephalomyelitis (EAE) in C57BL/6 mice.
79 stigation of the development of experimental allergic encephalomyelitis (EAE) in CD40L-deficient mice
80 cyte glycoprotein (MOG)-induced experimental allergic encephalomyelitis (EAE) in marmosets.
81 dendrocyte glycoprotein-induced experimental allergic encephalomyelitis (EAE) in normal mice.
82 on and development of relapsing experimental allergic encephalomyelitis (EAE) in SJL mice.
83 t of fatal CD4+ T cell-mediated experimental allergic encephalomyelitis (EAE) in susceptible female L
84 sing the demyelinating model of experimental allergic encephalomyelitis (EAE) in the common marmoset.
85 udy, we used uric acid to treat experimental allergic encephalomyelitis (EAE) in the PLSJL strain of
86 5- RMTCs, prevented and treated experimental allergic encephalomyelitis (EAE) induced with MBP89-101.
87                                 Experimental allergic encephalomyelitis (EAE) is a CD4(+) Th1 cell-me
88                                 Experimental allergic encephalomyelitis (EAE) is a CNS autoimmune dis
89  MS is immune mediated and that experimental allergic encephalomyelitis (EAE) is a suitable model to
90                                 Experimental allergic encephalomyelitis (EAE) is a T cell-mediated au
91                                 Experimental allergic encephalomyelitis (EAE) is a T cell-mediated au
92                                 Experimental allergic encephalomyelitis (EAE) is a Th1 cell-mediated
93                                 Experimental allergic encephalomyelitis (EAE) is a Th1-mediated infla
94                          Murine experimental allergic encephalomyelitis (EAE) is a useful model for t
95                                 Experimental allergic encephalomyelitis (EAE) is a widely used animal
96                                 Experimental allergic encephalomyelitis (EAE) is an animal model for
97 cyte glycoprotein (MOG) induced experimental allergic encephalomyelitis (EAE) is an animal model for
98                                 Experimental allergic encephalomyelitis (EAE) is an autoimmune diseas
99                                 Experimental allergic encephalomyelitis (EAE) is an autoimmune diseas
100                                 Experimental allergic encephalomyelitis (EAE) is an inflammatory demy
101                                 Experimental allergic encephalomyelitis (EAE) is an inflammatory, CD4
102                                 Experimental allergic encephalomyelitis (EAE) is induced by T cell-me
103 inating disease of the CNS, and experimental allergic encephalomyelitis (EAE) is its principal autoim
104                                 Experimental allergic encephalomyelitis (EAE) is the animal model for
105                                 Experimental allergic encephalomyelitis (EAE) is the animal model for
106                                 Experimental allergic encephalomyelitis (EAE) is the principal animal
107                                 Experimental allergic encephalomyelitis (EAE) is the principal geneti
108 cells in multiple sclerosis and experimental allergic encephalomyelitis (EAE) lesions but their role
109 Ag-specifically treating murine experimental allergic encephalomyelitis (EAE) mediated by MBP89-101-s
110 erosis and in its animal model, experimental allergic encephalomyelitis (EAE) remain equivocal.
111 ic autoimmune diseases, such as experimental allergic encephalomyelitis (EAE) the principal animal mo
112 tation and T cell activation in experimental allergic encephalomyelitis (EAE) was evaluated in wild-t
113                      Monophasic experimental allergic encephalomyelitis (EAE) was induced in a cohort
114 t in a second autoimmune model, experimental allergic encephalomyelitis (EAE) was induced in B10.D1-H
115 oned Th1 cells, the severity of experimental allergic encephalomyelitis (EAE) was slightly increased.
116   Gender-related differences in experimental allergic encephalomyelitis (EAE) were examined in the SJ
117      A.SW mice develop PP or SP-experimental allergic encephalomyelitis (EAE) with large areas of dem
118                                 Experimental allergic encephalomyelitis (EAE), a demyelinating diseas
119                                 Experimental allergic encephalomyelitis (EAE), a model of central ner
120  sodium channels along axons in experimental allergic encephalomyelitis (EAE), a model of multiple sc
121 ent of Ag-specific Th1 cells in experimental allergic encephalomyelitis (EAE), a model of multiple sc
122 n C57BL/6 (B6) strain-dependent experimental allergic encephalomyelitis (EAE), a model of primary pro
123 gnificantly reduced severity of experimental allergic encephalomyelitis (EAE), a murine model of mult
124  lyn gene on the development of experimental allergic encephalomyelitis (EAE), a well-established Th1
125 ils a method to actively induce experimental allergic encephalomyelitis (EAE), a widely used animal m
126 ession in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal model for MS
127 amined in Lewis rats with acute experimental allergic encephalomyelitis (EAE), an animal model for MS
128 ive cytokines and their role in experimental allergic encephalomyelitis (EAE), an animal model for mu
129 that Tkip protects mice against experimental allergic encephalomyelitis (EAE), an animal model for mu
130  been developed that ameliorate experimental allergic encephalomyelitis (EAE), an animal model for th
131 tration of UA is therapeutic in experimental allergic encephalomyelitis (EAE), an animal model of MS.
132 spinal cords of Lewis rats with experimental allergic encephalomyelitis (EAE), an animal model of MS.
133 sts reduce clinical severity of experimental allergic encephalomyelitis (EAE), an animal model of mul
134 ocess in adoptively transferred experimental allergic encephalomyelitis (EAE), an animal model of mul
135                 We examined how experimental allergic encephalomyelitis (EAE), an animal model of mul
136 hite matter from marmosets with experimental allergic encephalomyelitis (EAE), an animal model of mul
137 ocess of adoptively transferred experimental allergic encephalomyelitis (EAE), an animal model of rel
138 would be expected to exacerbate experimental allergic encephalomyelitis (EAE), an animal model of the
139                                 Experimental allergic encephalomyelitis (EAE), an autoimmune model of
140  to multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE), but multiple additiona
141 covery from monophasic clinical experimental allergic encephalomyelitis (EAE), can be induced to deve
142 ted a model autoimmune disease, experimental allergic encephalomyelitis (EAE), even after epitope spr
143 ) of mice with actively induced experimental allergic encephalomyelitis (EAE), that expresses OX-40L.
144 d, and Ab inhibition studies in experimental allergic encephalomyelitis (EAE), the animal model for m
145 mune disease, recent studies in experimental allergic encephalomyelitis (EAE), the animal model of mu
146 autoantigen capable of inducing experimental allergic encephalomyelitis (EAE), the animal model of mu
147 mine (HA) is a key regulator of experimental allergic encephalomyelitis (EAE), the autoimmune model o
148 s and during the development of experimental allergic encephalomyelitis (EAE), the contributions of I
149  SJL/J) F(2) intercross mice to experimental allergic encephalomyelitis (EAE), the foremost animal mo
150                                 Experimental allergic encephalomyelitis (EAE), the principal animal m
151                                 Experimental allergic encephalomyelitis (EAE), the principal animal m
152               Susceptibility to experimental allergic encephalomyelitis (EAE), the principal animal m
153 nd relapsing-remitting forms of experimental allergic encephalomyelitis (EAE), the principal autoimmu
154  component in susceptibility to experimental allergic encephalomyelitis (EAE), the principal autoimmu
155 , we used a murine model of MS, experimental allergic encephalomyelitis (EAE), to assess the potentia
156 stem was devised and applied to experimental allergic encephalomyelitis (EAE), to evaluate the contri
157 lycoprotein MOG(35-55)- induced experimental allergic encephalomyelitis (EAE), we assessed clinical s
158 stem for tolerance induction in experimental allergic encephalomyelitis (EAE), we created single-chai
159 tic nerves of mice induced with experimental allergic encephalomyelitis (EAE), with a focus on long-t
160 s and inflammatory responses in experimental allergic encephalomyelitis (EAE)-induced mice.
161 ein (MBP)-specific T cells from experimental allergic encephalomyelitis (EAE)-susceptible SJL (H-2(s)
162 els along demyelinated axons in experimental allergic encephalomyelitis (EAE).
163 nduced and spontaneous forms of experimental allergic encephalomyelitis (EAE).
164 with oral glatiramer acetate in experimental allergic encephalomyelitis (EAE).
165  peptide 35-55 in CFA to induce experimental allergic encephalomyelitis (EAE).
166 cytes into the CNS of mice with experimental allergic encephalomyelitis (EAE).
167 nesis of multiple sclerosis and experimental allergic encephalomyelitis (EAE).
168  autoimmune diseases, including experimental allergic encephalomyelitis (EAE).
169  both clinical and histological experimental allergic encephalomyelitis (EAE).
170 d (FasL) in the pathogenesis of experimental allergic encephalomyelitis (EAE).
171  autoimmune diseases, including experimental allergic encephalomyelitis (EAE).
172 effects in an autoimmune model, experimental allergic encephalomyelitis (EAE).
173 he optic nerves of animals with experimental allergic encephalomyelitis (EAE).
174 ses multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE).
175 onsible for the pathogenesis of experimental allergic encephalomyelitis (EAE).
176 this T cell surface molecule in experimental allergic encephalomyelitis (EAE).
177 sensitivity (DTH) responses and experimental allergic encephalomyelitis (EAE).
178  susceptibility to induction of experimental allergic encephalomyelitis (EAE).
179 tter of the CNS and symptoms of experimental allergic encephalomyelitis (EAE).
180 s ameliorate MS-like disease in experimental allergic encephalomyelitis (EAE).
181 ne model of multiple sclerosis, experimental allergic encephalomyelitis (EAE).
182  in both multiple sclerosis and experimental allergic encephalomyelitis (EAE).
183 ns and proved effective against experimental allergic encephalomyelitis (EAE).
184 s also not available for murine experimental allergic encephalomyelitis (EAE); the low number of T ce
185 " (healthy) and "disease-like" [experimental allergic encephalomyelitis (EAE)] animals.
186 e central nervous system during experimental allergic encephalomyelitis express the C5aR mRNA.
187 ion of myelin from animals with experimental allergic encephalomyelitis had slightly lower values of
188 y resistant to the induction of experimental allergic encephalomyelitis, implying the involvement of
189 nity, particularly diabetes and experimental allergic encephalomyelitis in animal models.
190 c T cells to induce symptoms of experimental allergic encephalomyelitis in animal models.
191 ys the onset of antigen-induced experimental allergic encephalomyelitis in myelin basic protein-T cel
192  adjuvant-induced arthritis and experimental allergic encephalomyelitis in rodents.
193          After the induction of experimental allergic encephalomyelitis in SJL mice with proteolipid
194 pe switching and attenuation of experimental allergic encephalomyelitis indicate that NTB-A is import
195 usceptible to acute early-phase experimental allergic encephalomyelitis indicating that H1R signaling
196  to the amelioration of ongoing experimental allergic encephalomyelitis induced by the transfer of pr
197  aggressive T cells and reverse experimental allergic encephalomyelitis induced with free peptides.
198 ssible autoantigens, we studied experimental allergic encephalomyelitis, induced by myelin oligodendr
199 f protective cytokines prior to experimental allergic encephalomyelitis induction and decreased effec
200 and promoted protection against experimental allergic encephalomyelitis involving diverse T cell spec
201                                 Experimental allergic encephalomyelitis is a prototypic autoimmune di
202 re precisely map these TMEV and experimental allergic encephalomyelitis loci relative to each other,
203 tively reduces disease in a rat experimental allergic encephalomyelitis model of multiple sclerosis.
204  oxide and peroxynitrite in the experimental allergic encephalomyelitis model.
205 se of neural inflammation in an experimental allergic encephalomyelitis model.
206 utoimmune encephalopathy in the experimental allergic encephalomyelitis model.
207 endroglial glycoprotein-induced experimental allergic encephalomyelitis (MOG-EAE).
208  vs risk of immune deviation in experimental allergic encephalomyelitis of SJL mice induced by MP4, a
209  T cell immunity, IgG1 Abs, and experimental allergic encephalomyelitis protection, and all three wer
210                    MOBP-induced experimental allergic encephalomyelitis shows a severe clinical cours
211 n an adoptive transfer model of experimental allergic encephalomyelitis, stimulation of lymph node ce
212 le in T cells fully complements experimental allergic encephalomyelitis susceptibility and the produc
213 R(-/-)) are more susceptible to experimental allergic encephalomyelitis than mice sufficient for the
214 ld mice are less susceptible to experimental allergic encephalomyelitis than their wild-type counterp
215 stration in a marmoset model of experimental allergic encephalomyelitis that closely resembles the hu
216  plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune model of mult
217  plays a key regulatory role in experimental allergic encephalomyelitis, the autoimmune model of mult
218 neutral proteinase (calpain) in experimental allergic encephalomyelitis, the corresponding animal mod
219 There are a variety of forms of experimental allergic encephalomyelitis, the most commonly studied an
220 n acute and relapsing-remitting experimental allergic encephalomyelitis, the neutrophil chemoattracta
221 to histamine, a subphenotype of experimental allergic encephalomyelitis, the principal autoimmune mod
222 ofilament on thickened axons in experimental allergic encephalomyelitis tissue.
223 s or CNS of wild-type mice with experimental allergic encephalomyelitis to determine their relatednes
224 se severity in animal models of experimental allergic encephalomyelitis, type I diabetes, and several
225 r histological manifestation of experimental allergic encephalomyelitis unless pertussis toxin is inj
226 e unable to resist or alleviate experimental allergic encephalomyelitis when treated with Ig-myelin o

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top